Morgens Waterfall Vintiadis & CO Inc Reata Pharmaceuticals Inc Transaction History

Morgens Waterfall Vintiadis & CO Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$93.53 - $163.34 $1.87 Million - $3.27 Million	-20,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$126.3 - $176.56 $1.77 Million - $2.47 Million	14,000 Added 233.33%	20,000 $3.12 Million
Q1 2020 May 15, 2020	SELL	$124.16 - $247.74 $2.81 Million - $5.6 Million	-22,600 Reduced 79.02%	6,000 $866,000
Q4 2019 Feb 14, 2020	SELL	$74.57 - $217.92 $700,957 - $2.05 Million	-9,400 Reduced 24.74%	28,600 $5.85 Million
Q3 2019 Nov 14, 2019	BUY	$71.26 - $95.75 $260,099 - $349,487	3,650 Added 10.63%	38,000 $3.05 Million
Q2 2019 Aug 14, 2019	BUY	$77.72 - $94.35 $182,642 - $221,722	2,350 Added 7.34%	34,350 $3.24 Million
Q3 2018 Nov 14, 2018	SELL	$35.64 - $92.06 $285,120 - $736,480	-8,000 Reduced 20.0%	32,000 $2.62 Million
Q2 2018 Aug 14, 2018	BUY	$19.94 - $40.96 $797,600 - $1.64 Million	40,000 New	40,000 $1.4 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Morgens Waterfall Vintiadis & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Morgens Waterfall Vintiadis & CO Inc with notifications on news.